Infratrac believes that personalized medicine can be developed using point-of-care drug printing

Ended Cooperative Agreement Awarded

Award ID
70NANB23H209
Recipient
Awarding agency
Obligated
$400,000

Award facts

Assistance listing
11.620 Science, Technology, Business and/or Education Outreach
Completion date
Place of performance
Silver Spring, MD 20910, USA

Award details come from USAspending.gov.

Description

Activities
In phase II, infratrac will demonstrate how IT will detect and control for safety and quality issues in point-of-care 3D drug printing. They plan to expand the scope of research and development to include additional drugs and doses, include more failure types, and perform detection and predication capability into a commercially-viable tool for process control.
Expected outcomes
Infratrac?S technology aims to provide hospital pharmacies and other point-of-care facilities with a mechanism to protect patients by preventing the inadvertent administration of 3D printed doses containing either too much or too little of the prescribed medication.
Intended beneficiaries
Hospitals, pharmacies, the general public, especially children and seniors, those with allergies, and other patients requiring non-standard, complex, easily swallowed, or in-between dosing of medications.
Subrecipient activities
Recipient will use the following subcontractors:1. Applied pharmaceutics lab at university of MD school of PHARMACY2. Fabrx - a company that prints 3D printed dosage forms

Quick answers

Who received award 70NANB23H209?

70NANB23H209 was awarded to Infratrac Inc. by National Institute of Standards and Technology (Department of Commerce) on September 5, 2023.

How much is award 70NANB23H209 worth?

$400,000 has been obligated on 70NANB23H209.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award